Cancer Vaccines Market Analysis

The market is segmented by vaccine, by indication, by technology and by region, out of which, the vaccine segment is segmented into therapeutic cancer vaccines and preventive cancer vaccines. The segment for preventive cancer vaccines is anticipated to hold the largest share in the cancer vaccines market on account of growing demand for these vaccines by people for prevention of cancer. Preventive cancer vaccines reduce the risk of infection by cancer causing organisms and help the body to build up immunity against them by creating antibodies. The therapeutic cancer vaccines segment is predicted to grow at the highest rate over the forecast period as a result of high demand for vaccines for the treatment of cancer. Based on technology, the cancer vaccines market is segmented into recombinant vaccine, dendritic cells vaccine, whole cell vaccine, adjuvant vaccine and viral vector & DNA vaccine. According to the National Cancer Institute, the vaccines for prevention of disease causing HPV that are approved for use in the United States include Cervarix, Gardasil and Gardasil 9. These prevent infection from HPV type 16 and 18, which are estimated to cause around 70% of all cervical cancers.

Our in-depth analysis of the global market includes the following segments